Naslov
Vaccine effectiveness against influenza A(H1N1)pdm09, A(H3N2) and B: Results from the 2019/20 European I-MOVE primary care multicentre study

Autori
Kissling, E ; Pozo, F ; Buda, S ; Vilcu, A ; Mazagatos-Ateca, C ; Brytting, M ; Dijkstra, F ; Domegan, L ; Machado, A ; Lazar, M ; Višekruna Vucina, V ; Dürrwald, R ; Behillil, S ; Larrauri, A ; Enkirch, T ; Hooiveld, M ; O’Donnell, J ; Guiomar, R ; Cherciu, C ; Petrovic, G ; Penttinen, P ; M. Valenciano, M ; 22, I-MOVE primary care study team

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
ESCAIDE 2020 Abstract book / Catchpole, Mike - , 2020, 39-39

Skup
European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) 2022

Mjesto i datum
Online, 24.11.2020. - 27.11.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Influenza, vaccine effectiveness, Multicentre study, case control study, Europe

Sažetak
Background: In 2019/20 the I-MOVE network conducted a multicentre test-negative study using sentinel primary care networks in nine European countries to measure vaccine effectiveness (VE) against influenza A(H1N1)pdm09, A(H3N2) and B. Methods: Primary care practitioners swabbed a systematic sample of patients presenting with influenza like illness (ILI), collecting also information on demographics, vaccination and clinical characteristics. Cases were RTPCR positive for influenza A(H1N1)pdm09, A(H3N2) or B and controls were negative for any influenza. We calculated VE using logistic regression, adjusting for study site and potential confounders (age, sex, onset time, presence of chronic conditions). We stratified VE by age-group (0–14, 15–64, ≥65 years). Results: We included 8457 ILI patients of whom 1499, 841 and 1214 were influenza A(H1N1)pdm09, A(H3N2), and B positive, respectively. Where B/lineage was determined (938/1214 influenza B viruses), 923 (98%) were B/ Victoria. Overall VE against influenza A(H1N1)pdm09 was 45% (95%CI: 29–57), with 57% (95%CI: 17–78) and 50% (95%CI: 30–64) among those aged 0–14 and 15–64, respectively. Overall VE against influenza A(H3N2) was 49% (95%CI: 30–62), with 60% (95%CI: 7–82) and 59% (95%CI: 37–74) among those aged 0–14 and 15–64, respectively. Overall VE against influenza B was 57% (95%CI: 39–70), with 43% (95%CI: -3–69) and 63% (95%CI: 37–73 among those aged 0–14 and 15–64, respectively. Influenza positive cases among those aged ≥65 years were too few to measure adjusted VE. Conclusions: The 2019/20 VE against all circulating influenza (sub)types ranged between 43 and 63% overall and among those aged <65 years. Our results suggest that influenza vaccination may have conferred protection in up to two-thirds of vaccinated individuals during the 2019/20 influenza season.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA